(ERA) Eramet - Ratings and Ratios
Nickel, Manganese, Alloys
Description: ERA Eramet August 13, 2025
Eramet SA (ERA) is a French multinational mining and metallurgy company operating in the Diversified Metals & Mining sub-industry. The companys stock is listed as a common stock with a market capitalization of approximately €1.364 billion.
To evaluate Eramets financial health and profitability, key performance indicators (KPIs) such as Return on Equity (RoE) and Price-to-Earnings (P/E) ratio are essential. Eramets RoE stands at 7.76%, indicating a moderate return on shareholders equity. The forward P/E ratio is 10.16, suggesting that the market expects the company to generate earnings growth in the future.
Eramets business is heavily influenced by commodity prices, particularly those of nickel, manganese, and lithium, which are key components in the production of stainless steel, batteries, and other high-tech applications. The companys financial performance is closely tied to the global demand for these commodities, driven by trends such as the electrification of transportation and infrastructure development.
Key economic drivers for Eramet include global commodity prices, demand from major end-markets such as the automotive and construction industries, and the overall state of the global economy. The companys operational efficiency, cost management, and ability to adapt to changing market conditions will also impact its financial performance.
From a trading perspective, Eramets stock has shown a beta of 1.527, indicating a relatively high level of volatility compared to the broader market. The stocks current price is €51.70, with a 52-week high and low of €71.88 and €40.52, respectively. Average trading volume is around 45,210 shares.
ERA Stock Overview
| Market Cap in USD | 2,001m |
| Sub-Industry | Diversified Metals & Mining |
| IPO / Inception |
ERA Stock Ratings
| Growth Rating | -1.20% |
| Fundamental | 13.4% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -3.55% |
| Analyst Rating | - |
ERA Dividends
| Dividend Yield 12m | 2.24% |
| Yield on Cost 5y | 6.72% |
| Annual Growth 5y | -22.54% |
| Payout Consistency | 60.3% |
| Payout Ratio | 300.0% |
ERA Growth Ratios
| Growth Correlation 3m | 79.2% |
| Growth Correlation 12m | -2.3% |
| Growth Correlation 5y | -8.8% |
| CAGR 5y | -4.04% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.06 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.12 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | -10.50 |
| Beta | 1.414 |
| Volatility | 41.57% |
| Current Volume | 28.6k |
| Average Volume 20d | 48.7k |
| Stop Loss | 57.9 (-4.1%) |
| Signal | -0.13 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-127.0m TTM) > 0 and > 6% of Revenue (6% = 357.6m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -23.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.53% (prev 17.17%; Δ -4.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 114.0m > Net Income -127.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.88b) to EBITDA (441.0m) ratio: 4.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.6m) change vs 12m ago -0.69% (target <= -2.0% for YES) |
| Gross Margin 45.22% (prev 17.85%; Δ 27.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.33% (prev 104.1%; Δ -8.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.39 (EBITDA TTM 441.0m / Interest Expense TTM 217.0m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 13.39
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -40.30% = -5.0 |
| 3. FCF Margin -23.27% = -7.50 |
| 4. Debt/Equity 2.37 = 0.21 |
| 5. Debt/Ebitda 4.25 = -2.50 |
| 6. ROIC - WACC (= -10.04)% = -12.50 |
| 7. RoE -8.95% = -1.49 |
| 8. Rev. Trend -60.59% = -4.54 |
| 9. EPS Trend -35.65% = -1.78 |
What is the price of ERA shares?
Over the past week, the price has changed by -1.39%, over one month by +7.77%, over three months by +8.06% and over the past year by +15.18%.
Is Eramet a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ERA is around 55.63 EUR . This means that ERA is currently overvalued and has a potential downside of -7.82%.
Is ERA a buy, sell or hold?
What are the forecasts/targets for the ERA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52 | -13.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 61.2 | 1.4% |
ERA Fundamental Data Overview January 01, 1970
Market Cap EUR = 1.72b (1.72b EUR * 1.0 EUR.EUR)
P/E Forward = 10.1626
P/S = 0.5893
P/B = 1.5802
Beta = 1.414
Revenue TTM = 5.96b EUR
EBIT TTM = -84.0m EUR
EBITDA TTM = 441.0m EUR
Long Term Debt = 2.02b EUR (from longTermDebt, last quarter)
Short Term Debt = 406.0m EUR (from shortTermDebt, last quarter)
Debt = 2.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.88b EUR (from netDebt column, last quarter)
Enterprise Value = 3.44b EUR (1.72b + Debt 2.47b - CCE 746.0m)
Interest Coverage Ratio = -0.39 (Ebit TTM -84.0m / Interest Expense TTM 217.0m)
FCF Yield = -40.30% (FCF TTM -1.39b / Enterprise Value 3.44b)
FCF Margin = -23.27% (FCF TTM -1.39b / Revenue TTM 5.96b)
Net Margin = -2.13% (Net Income TTM -127.0m / Revenue TTM 5.96b)
Gross Margin = 45.22% ((Revenue TTM 5.96b - Cost of Revenue TTM 3.27b) / Revenue TTM)
Gross Margin QoQ = 65.07% (prev 52.50%)
Tobins Q-Ratio = 0.56 (Enterprise Value 3.44b / Total Assets 6.15b)
Interest Expense / Debt = 3.00% (Interest Expense 74.0m / Debt 2.47b)
Taxrate = -33.58% (negative due to tax credits) (45.0m / -134.0m)
NOPAT = -112.2m (EBIT -84.0m * (1 - -33.58%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.54 (Total Current Assets 2.14b / Total Current Liabilities 1.39b)
Debt / Equity = 2.37 (Debt 2.47b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 4.25 (Net Debt 1.88b / EBITDA 441.0m)
Debt / FCF = -1.35 (negative FCF - burning cash) (Net Debt 1.88b / FCF TTM -1.39b)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.07% (Net Income -127.0m / Total Assets 6.15b)
RoE = -8.95% (Net Income TTM -127.0m / Total Stockholder Equity 1.42b)
RoCE = -2.44% (EBIT -84.0m / Capital Employed (Equity 1.42b + L.T.Debt 2.02b))
RoIC = -3.07% (negative operating profit) (NOPAT -112.2m / Invested Capital 3.65b)
WACC = 6.97% (E(1.72b)/V(4.19b) * Re(11.23%) + D(2.47b)/V(4.19b) * Rd(3.00%) * (1-Tc(-0.34)))
Discount Rate = 11.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.38%
Fair Price DCF = unknown (Cash Flow -1.39b)
EPS Correlation: -35.65 | EPS CAGR: -24.69% | SUE: 0.0 | # QB: 0
Revenue Correlation: -60.59 | Revenue CAGR: -14.28% | SUE: -0.07 | # QB: 0